Rigas JR - Search Results

1

Lung cancer in a U.S. population with low to moderate arsenic exposure.

Heck JE, Andrew AS, Onega T, Rigas JR, Jackson BP, Karagas MR, Duell EJ. Heck JE, et al. Among authors: rigas jr. Environ Health Perspect. 2009 Nov;117(11):1718-23. doi: 10.1289/ehp.0900566. Epub 2009 Jul 2. Environ Health Perspect. 2009. PMID: 20049123 Free PMC article.

2

Metabolic phenotypes of retinoic acid and the risk of lung cancer.

Rigas JR, Miller VA, Zhang ZF, Klimstra DS, Tong WP, Kris MG, Warrell RP Jr. Rigas JR, et al. Cancer Res. 1996 Jun 15;56(12):2692-6. Cancer Res. 1996. PMID: 8665495

3

Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.

Rigas JR, Kris MG, Gralla RJ, Heelan RT, Marks LD. Rigas JR, et al. Invest New Drugs. 1991 May;9(2):187-90. doi: 10.1007/BF00175087. Invest New Drugs. 1991. PMID: 1651908 Clinical Trial.

4

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.

Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KM, Venkatraman ES, Woolley K, Heelan RT, Kris MG. Miller VA, et al. Among authors: rigas jr. Cancer. 1995 Feb 15;75(4):968-72. doi: 10.1002/1097-0142(19950215)75:4<968::aid-cncr2820750411>3.0.co;2-y. Cancer. 1995. PMID: 7842417 Clinical Trial.

5

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB. Bruno R, et al. Among authors: rigas jr. J Clin Oncol. 1998 Jan;16(1):187-96. doi: 10.1200/JCO.1998.16.1.187. J Clin Oncol. 1998. PMID: 9440742 Clinical Trial.

6

Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer.

Black CC, Turk MJ, Dragnev K, Rigas JR. Black CC, et al. Among authors: rigas jr. Lung. 2013 Jun;191(3):265-70. doi: 10.1007/s00408-013-9455-7. Epub 2013 Mar 15. Lung. 2013. PMID: 23494387

7

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Planchard D, et al. Among authors: rigas jr. Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6. Lancet Oncol. 2016. PMID: 27283860 Free PMC article. Clinical Trial.

8

Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non-Small-Cell Lung Cancer in the United States.

Kelly RJ, Turner R, Chen YW, Rigas JR, Fernandes AW, Karve S. Kelly RJ, et al. Among authors: rigas jr. J Oncol Pract. 2019 Aug;15(8):e717-e727. doi: 10.1200/JOP.18.00762. Epub 2019 Jun 25. J Oncol Pract. 2019. PMID: 31237806

9

Docetaxel in stage III and IV non-small cell lung cancer.

Rigas JR. Rigas JR. Eur J Cancer. 1995;31A Suppl 4:S18-20. doi: 10.1016/0959-8049(95)00358-p. Eur J Cancer. 1995. PMID: 7577100 Clinical Trial.

10

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.

Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, Heelan RT. Francis PA, et al. Among authors: rigas jr. J Clin Oncol. 1994 Jun;12(6):1232-7. doi: 10.1200/JCO.1994.12.6.1232. J Clin Oncol. 1994. PMID: 7911159 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

96 results

Search Page